logo

For the Inventor, By the Inventor

Bedford, MA, United States of America

Celgene Avilomics Research, Inc.

Calculating rank
USPTO Granted Patents = 44

% Expired Patents = 45.5



Forward Citations = 927

Loading Chart...
Loading Chart...

41 inventors (with patents filed for the assignee):

goldMedal Juswinder Singh (31 out of 68 patents)

silverMedal Russell Colyn Petter (31 out of 82 patents)

bronzeMedal Deqiang Niu (25 out of 83 patents)

4.  Arthur F Kluge (20 out of 96 patents)

5.  Richland Wayne Tester (19 out of 30 patents)

6.  Lixin Qiao (18 out of 40 patents)

7.  Shomir Ghosh (11 out of 71 patents)

8.  William Frederick Westlin, Iii (9 out of 15 patents)

9.  Hormoz Mazdiyasni (8 out of 19 patents)

10.  Zhendong Zhu (8 out of 20 patents)

11.  Kwangho Lee (7 out of 28 patents)

12.  Mei Lai (4 out of 16 patents)

13.  Matthew Frank Baevsky (4 out of 9 patents)

14.  Steven Richard Witowski (4 out of 10 patents)

15.  Lisa Beebe (3 out of 4 patents)


Core Competencies:
ERK Inhibitors
Protein Kinase Conjugates
HCV Protease Inhibitors
Epidermal Growth Factor Receptor
Heteroaryl Compounds
Pyrimidine Compounds
Bruton's Tyrosine Kinase
MK2 Inhibitors
Solid Forms
Mutant-Selective Inhibitors
Substituted Pyrimidines
Heterocyclic Compounds

44 patents:

1. 9561228 - ERK inhibitors and uses thereof (2017-02-07),
2. 9556426 - Protein kinase conjugates and inhibitors (2017-01-31),
3. 9549927 - Heteroaryl compounds and uses thereof (2017-01-24),
4. 9540335 - Salts of an epidermal growth factor receptor kinase inhibitor (2017-01-10),
5. 9539255 - Solid forms of an epidermal growth factor receptor kinase inhibitor (2017-01-10),
6. 9504686 - ERK inhibitors and uses thereof (2016-11-29),
7. 9492471 - Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase (2016-11-15),
8. 9458175 - MK2 inhibitors and uses thereof (2016-10-04),
9. 9422333 - HCV protease inhibitors and uses thereof (2016-08-23),
10. 9415049 - Heteroaryl compounds and uses thereof (2016-08-16),
11. 9409921 - 2,4-disubstituted pyrimidines as kinase inhibitors (2016-08-09),
12. 9409887 - Mutant-selective EGFR inhibitors and uses thereof (2016-08-09),
13. 9393246 - 4,6-disubstituted pyrimidines as kinase inhibitors (2016-07-19),
14. 9375431 - 2,4-disubstituted pyrimidine compounds useful as kinase inhibtors (2016-06-28),
15. 9364476 - Methods of treating a Bruton's Tyrosine Kinase disease or disorder (2016-06-14),
Company Overview
Celgene Avilomics Research, Inc., based in Bedford, MA, specializes in the development of innovative therapeutic solutions targeting various protein kinases and their pathways. The company focuses on advancing treatments through its expertise in ERK inhibitors, protein kinase conjugates, and heteroaryl compounds. With a commitment to addressing complex diseases, Celgene Avilomics is engaged in research on key areas such as epidermal growth factor receptor kinase and Bruton’s tyrosine kinase, aiming to deliver effective therapies for patients.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Nov 10 2026

44 Patents

#15 in Bedford, MA

#456 in Massachusetts

#7,970 in US

#15,787 in the World

Bedford, MA (US)
Bedford, MA, United States of America

Celgene Avilomics Research, Inc.

Forward Citations = 927

41 inventors:

goldMedal Juswinder Singh (31 out of 68 patents)

silverMedal Russell Colyn Petter (31 out of 82 patents)

bronzeMedal Deqiang Niu (25 out of 83 patents)

4.  Arthur F Kluge (20 out of 96 patents)

5.  Richland Wayne Tester (19 out of 30 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Celgene Avilomics Research, Inc.. Retrieved from https://idiyas.com/company/celgene-avilomics-research

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…